ACT Genomics Expands Cancer Genomic Testing Panel to 101 Genes with 7-Day Turnaround Time

Key Takeaways

• ACT Genomics upgraded its ACTDrug genomic testing panel from previous version to comprehensive 101-gene analysis for cancer patients
• New testing service delivers results in seven working days, accelerating treatment decisions for newly diagnosed advanced or metastatic cancer patients
• Enhanced panel provides physicians with more comprehensive genomic information to guide personalized cancer treatment strategies

---

ACT Genomics announced on April 20, 2026, a major enhancement to its ACTDrug® genomic profiling service, expanding the next-generation sequencing (NGS) panel to analyze 101 clinically relevant genes while maintaining a seven-working-day turnaround time for results.

The Taipei-based genomics company’s upgraded testing platform targets newly diagnosed patients with advanced or metastatic cancer, providing oncologists with comprehensive genetic information to inform treatment decisions. The expanded gene panel represents a significant advancement in precision medicine capabilities for cancer care in the Asia-Pacific region.

Enhanced Genomic Profiling for Cancer Treatment

The ACTDrug® series upgrade addresses the growing demand for rapid, comprehensive genomic testing in oncology. By analyzing 101 clinically relevant genes, the enhanced panel enables physicians to identify specific genetic mutations and biomarkers that can guide targeted therapy selection for individual patients.

The seven-day turnaround time is particularly crucial for patients with advanced or metastatic cancer, where treatment delays can significantly impact outcomes. This timeline allows oncologists to quickly access genetic information needed for personalized treatment planning.

Market Impact and Clinical Significance

ACT Genomics’ expanded testing capability strengthens its position in the competitive genomic testing market, particularly in precision oncology. The 101-gene panel covers a broader range of actionable mutations compared to smaller targeted panels, potentially identifying more treatment options for patients.

The upgrade reflects the industry trend toward comprehensive genomic profiling as standard care for cancer patients. Healthcare systems increasingly recognize that broader genetic testing can improve treatment outcomes while potentially reducing overall healthcare costs by avoiding ineffective therapies.

Future of Precision Medicine

This enhancement positions ACT Genomics to better serve the growing precision medicine market in Asia-Pacific, where demand for advanced diagnostic capabilities continues expanding. The improved testing platform may also support clinical research initiatives and drug development programs requiring comprehensive genomic data.

---

Frequently Asked Questions

What does the 101-gene panel test for in cancer patients?

The ACTDrug® 101-gene panel analyzes clinically relevant genetic mutations and biomarkers that help oncologists select targeted therapies and personalized treatment approaches for patients with advanced or metastatic cancer.

How quickly can patients receive their genomic test results?

ACT Genomics delivers results within seven working days from sample receipt, enabling rapid treatment decision-making for newly diagnosed cancer patients who need immediate therapeutic intervention.

How does this compare to other cancer genomic testing options?

The 101-gene panel offers more comprehensive analysis than smaller targeted panels while maintaining competitive turnaround times, providing broader mutation detection capabilities that may identify additional treatment options for patients.